scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00280-011-1733-6 |
P698 | PubMed publication ID | 21938545 |
P50 | author | Chandra Belani | Q40073451 |
P2093 | author name string | Paul Haluska | |
Ramesh K Ramanathan | |||
S Gail Eckhardt | |||
Stephen Leong | |||
Karsten Witt | |||
Cindy L O'Bryant | |||
Suresh Ramalingam | |||
Ramesh Boinpally | |||
Lee Rosen | |||
Balaji Venugopal | |||
Jeffry Evans | |||
Amy Franke | |||
P2860 | cites work | Erlotinib in previously treated non-small-cell lung cancer | Q29547546 |
EGFR antagonists in cancer treatment | Q29616740 | ||
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
Phase II study of erlotinib in patients with advanced biliary cancer | Q33997258 | ||
Transection of the oesophagus for bleeding oesophageal varices | Q34211834 | ||
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen | Q34451318 | ||
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
Clinical pharmacokinetics of tyrosine kinase inhibitors | Q34611569 | ||
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer | Q35956595 | ||
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers | Q37155636 | ||
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies | Q43658492 | ||
Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. | Q45970694 | ||
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity | Q46726161 | ||
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib | Q46809344 | ||
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. | Q51936030 | ||
P433 | issue | 3 | |
P921 | main subject | erlotinib | Q418369 |
P304 | page(s) | 605-612 | |
P577 | publication date | 2011-09-22 | |
P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
P1476 | title | An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. | |
P478 | volume | 69 |
Q28068579 | Cancer and liver cirrhosis: implications on prognosis and management |
Q26861560 | Hepatotoxicity Secondary to Chemotherapy |
Q35927299 | Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis |
Q54267525 | Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. |
Q49909297 | Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model. |
Q52666663 | Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation. |
Search more.